A kind of levetiracetam pharmaceutical composition and its preparation method and application

A composition and drug technology, applied in the field of medicine, can solve problems affecting the quality of life of patients, and achieve the effects of long-term treatment, improvement of compliance, and promotion of gastrointestinal motility

Active Publication Date: 2021-04-13
HARBIN ZHENBAO PHARMA +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, it seriously affects the quality of life of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of levetiracetam pharmaceutical composition and its preparation method and application
  • A kind of levetiracetam pharmaceutical composition and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0038] In the second aspect, the embodiment of the present invention also provides a preparation method of levetiracetam pharmaceutical composition, which comprises the following steps:

[0039] S1. Mix levetiracetam, microcrystalline cellulose, lactose and low-substituted hypromellose evenly, add starch slurry for granulation.

[0040] It specifically includes: first pulverize levetiracetam to 80-100 mesh, then mix microcrystalline cellulose, lactose and low-substituted hypromellose evenly, and mix levetiracetam evenly in an equal increment method, Add an appropriate amount of starch slurry (the ratio of microcrystalline cellulose to starch slurry is 1g:1-5ml, and the concentration of starch slurry is 5%), and granulate for 1-2 minutes. Wet granulation is carried out with a swing granulator, and the mesh number of the sieve is 20-22 mesh. Wet granules are placed in a high-efficiency boiling dryer, dried at 50-60°C, and the moisture content of the granules is controlled betwe...

Embodiment 1

[0050] Present embodiment provides a kind of levetiracetam pharmaceutical composition, and its preparation method is as follows:

[0051] S1. Raw material preparation: 200g of levetiracetam, 60g of microcrystalline cellulose, 60g of lactose, 10g of low-substituted hypromellose, 4g of magnesium stearate and 300ml of starch slurry;

[0052] S2. Granulation: pulverize levetiracetam to 100 meshes; then mix microcrystalline cellulose, lactose and low-substituted hypromellose evenly, and mix the mixture with levetiracetam evenly in an equal increment method , add starch slurry, granulate for 1-2 minutes. Wet sizing is carried out with a oscillating granulator, and the mesh number of the sieve is 20 mesh. Wet granules are placed in a high-efficiency fluidized dryer, and the dryer is preheated with wind at a temperature of 70°C for 10 minutes, and then dried at 60°C until the moisture content of the granules is between 1.5% and 6.5%. The dried granules are sized in a swing granulato...

Embodiment 2

[0054] Present embodiment provides a kind of levetiracetam pharmaceutical composition, and its preparation method is as follows:

[0055] S1. Preparation of materials: 350g of levetiracetam, 90g of microcrystalline cellulose, 90g of lactose, 9g of low-substituted hypromellose, 2g of magnesium stearate, 2g of gastric-soluble film coating premix and 300ml of starch slurry.

[0056] S2. Granulation: pulverize levetiracetam to 80 meshes; then mix microcrystalline cellulose, lactose and low-substituted hypromellose evenly, and mix the mixture with levetiracetam evenly in an equal increment method , add starch slurry, granulate for 1-2 minutes. Wet sizing is carried out with a oscillating granulator, and the mesh number of the sieve is 22 mesh. Wet granules are placed in a high-efficiency fluidized dryer, and the dryer is preheated with wind at 60°C for 15 minutes, and then dried at 50°C until the moisture content of the granules is between 1.5% and 6.5%. The dried granules are si...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of medicine, and provides a levetiracetam pharmaceutical composition and a preparation method and application thereof. The components of the levetiracetam pharmaceutical composition include 200-400 parts by weight of levetiracetam, 60-100 parts of microcrystalline cellulose, 60-100 parts of lactose, low-substituted hypromellose 6-12 parts and 1-4 parts of magnesium stearate; components also include starch slurry 90-300ml, and the consumption ratio of microcrystalline cellulose and starch slurry is 1g:1.5-5ml; its preparation method comprises mixing each component Make capsules or tablets evenly. By limiting the content of each component, the drug can be released slowly in the body, reducing the direct stimulation of levetiracetam to the gastrointestinal tract, thereby reducing its side effects, especially the occurrence of severe gastrointestinal reactions, and improving the drug safety of patients. Compliance and safety are conducive to long-term treatment.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a levetiracetam pharmaceutical composition and its preparation method and application. Background technique [0002] Levetiracetam is an antiepileptic drug, which is mainly used clinically for the additional treatment of partial seizures in adults and children over 4 years old with epilepsy. However, very large doses of levetiracetam can cause diarrhea in individual patients. When diarrhea exceeds 5 times a day or bloody diarrhea occurs, it is generally necessary to reduce the dose of the drug or stop the chemical drug immediately and treat it in time. Generally, after the drug is stopped, the treatment will be difficult to proceed smoothly, thereby affecting the curative effect of the treatment. [0003] The main cause of diarrhea in patients receiving chemical drugs is due to the direct inhibition or destruction of intestinal mucosal cells by the drugs, and it is also relate...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4015A61K47/38A61K47/26A61K47/36A61P25/08
CPCA61K31/4015A61K47/26A61K47/36A61K47/38A61P25/08
Inventor 方同华韩冰崔玉海高丽邢松岩
Owner HARBIN ZHENBAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap